drugset / Trial / NCT00003259

Vinorelbine in Treating Patients With Metastatic Prostate Cancer

NCT00003259 ↗

Phase 2 Completed 40 enrolled Swiss Cancer Institute
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating patients with metastatic prostate cancer that has not responded to hormone therapy.

Timeline

Start
1997-10
Primary completion
1999-09
Completion
1999-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Vinorelbine Small molecule 30 mg/m2 Intravenous

Indications